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Summary
Although the p53 tumor suppressor acts in a plethora of processes that influence cellular proliferation and survival, it
remains unclear which p53 functions are essential for tumor suppression and, as a consequence, are selected against
during tumor development. Using a mouse model harboring primary, genetically modified myc-driven lymphomas, we show
that disruption of apoptosis downstream of p53 by Bcl2 or a dominant-negative caspase 9 confers—like p53 loss—a
selective advantage, and completely alleviates pressure to inactivate p53 during lymphomagenesis. Despite their p53-null-
like aggressive phenotype, apoptosis-defective lymphomas that retain intact p53 genes do not display the checkpoint
defects and gross aneuploidy that are characteristic of p53 mutant tumors. Therefore, apoptosis is the only p53 function
selected against during lymphoma development, whereas defective cell-cycle checkpoints and aneuploidy are mere byprod-
ucts of p53 loss.
Introduction consequences of inactivating a specific p53 effector have not
been as severe as those obtained by inactivating p53 itself. For
example, inactivation of bax, a proapoptotic effector of p53,The p53 tumor suppressor was initially identified as the “guard-
ian of the genome” based on its ability to mediate a G1 arrest can accelerate tumor development in several settings, but not
to the same extent as loss of p53 (Eischen et al., 2001; Yin etfollowing DNA damage (Kastan et al., 1992; Lane, 1992). How-
ever, p53 is now known to act in many cellular processes, al., 1997). Since it is likely that p53 modulates apoptosis (and
other cellular processes) through multiple effectors, it is notincluding cell-cycle checkpoints, DNA repair, senescence, apo-
ptosis, angiogenesis, and the surveillance of genomic integrity possible to conclude that a nonapoptotic activity of p53 contrib-
utes to tumor suppression in these settings.(Evan and Vousden, 2001; Ko and Prives, 1996). In principle,
disruption of any one or combination of these activities may We hypothesized that complete ablation of crucial p53 ef-
fector functions may produce tumors that are phenotypicallyexplain the high frequency of p53 mutations in human tumors
(Hainaut et al., 1998). Most studies designed to identify relevant identical to those with p53 mutations yet retain wild-type p53.
To this end, we examined the ability of dominant-acting genesp53 tumor suppressor functions have examined the behavior
of p53 mutant tumor cells, or correlated loss of specific p53- that completely disable apoptosis downstream of p53 to pheno-
copy the effects of p53 mutations in the E-myc transgeniccontrolled functions with tumor progression in animal models
or cancer patients (Attardi and Jacks, 1999; Bardeesy et al., mouse. These mice overexpress the c-myc oncogene in the B
cell lineage and develop pre-B or B cell lymphoma by several1995; Kakolyris et al., 2000; Smith and Fornace, 1995). However,
neither approach distinguishes between those p53 functions months of age (Adams et al., 1985), and provide an ideal setting
in which to study p53 function during tumor development. First,that are actively selected against during tumorigenesis and
those that are simply consequences of p53 loss. tumors arising in these animals closely resemble human non-
Hodgkin’s lymphoma (Adams et al., 1985). Second, p53 actsAttempts to directly address this issue have used mouse
models to determine whether disruption of individual p53 ef- as a potent tumor suppressor in this model, since spontaneous
p53 mutations occur in a subset of E-myc lymphomas (Eischenfectors can recapitulate the effects of p53 inactivation during
tumorigenesis. However, in all of these studies, the biological et al., 1999; Schmitt et al., 1999). Third, experimental inactivation
S I G N I F I C A N C E
p53 mutations have been associated with defects in many cellular processes. In principle, the simultaneous loss of multiple p53
functions might provide an enormous advantage to p53 mutant tumor cells. Alternatively, disruption of a single p53 activity might
provide an essential capability, with the other defects arising as byproducts of p53 loss. Here we show that disruption of apoptosis
is the only consequence of p53 loss required for the generation of aggressive murine lymphomas. In contrast, other p53-related
defects, while present, have no further impact on tumor growth. Therefore, not all defects observed in p53 mutant tumors contribute
to the malignant phenotype. Understanding which p53 functions naturally suppress tumorigenesis in different settings should provide
a framework for developing rational therapies most likely to have tumoricidal potential.
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of p53 dramatically accelerates lymphoma onset and invasive-
ness (Schmitt et al., 1999). Finally, as shown here, genes can
be introduced into established lymphomas or premalignant he-
matopoietic stem cells ex vivo (Schmitt et al., 2000a), thereby
making the system experimentally tractable. This latter feature
allows one to study the impact of specific genes on tumor
behavior following transplantation into syngeneic recipients,
and to tag tumor cells with fluorescent proteins for whole body
imaging of tumor behavior in live mice.
Results
To determine the contribution of apoptosis to p53-mediated
tumor suppression, we utilized Bcl2 and a dominant-negative
caspase 9 (Pan et al., 1998) (C9DN) as moieties that act at
different levels downstream of p53 to disrupt apoptosis but not
other p53 effector functions (Chiou et al., 1994; Huang et al.,
1997; Soengas et al., 1999). Bcl2 or C9DN were introduced into
freshly isolated E-myc lymphoma cells (hereafter referred to
as controls [ctrl.]) or E-myc p53 null lymphomas (that arose
in p53/ animals that invariably lose the wild-type p53 allele
(Schmitt et al., 1999), see Table 1 for genotype nomenclature
of normal and lymphoma cells) using murine stem cell virus-
based retroviral vectors that coexpressed Bcl2 or C9DN with
green fluorescent protein (GFP) from a bicistronic message
(MSCV-bcl2 and MSCV-C9DN, respectively). As a control, the
same lymphomas were infected with a vector expressing GFP
alone (MSCV). The infection efficiency was typically greater than
70% as assessed by flow cytometry for GFP expression (data
not shown). Ctrl. lymphomas were substantially more sensitive
than p53 null lymphomas to treatment with mafosphamide (an
alkylating agent) or -irradiation (Figure 1A; compare MSCV
lanes). As predicted, both Bcl2 and C9DN markedly suppressed
apoptosis in ctrl. lymphomas but did not further reduce apopto-
Figure 1. Enrichment for apoptotic defects during lymphoma establishmentsis in p53 null lymphomas (Figure 1A). However, consistent with
A: Apoptosis upon exposure to DNA damaging treatments (mafosphamide,their distinct modes of action, Bcl2 prevented mitochondrial
MAF, 3 g/ml, over 6 hr, and IRR, 6 hr after 4 Gy -irradiation) in ctrl. (left)cytochrome c release, whereas C9DN did not (data not shown).
or p53 null (right) lymphoma cells in vitro. Cells were transduced with anTogether, these data imply that Bcl2 and C9DN can suppress
empty vector (MSCV) or retroviral constructs encoding bcl2 or a dominant-
apoptosis in lymphoma cells in a manner that is largely depen- negative activity of caspase 9 (C9DN) coexpressed with GFP. Apoptotic
dent on p53. cell death was analyzed by propidium iodide staining and flow cytometry,
and was measured as fractions with less than G1 DNA content. ResultsNext, we asked whether cells harboring apoptotic defects
shown represent the average of at least three independent experimentscould be selected for during tumor expansion by using an in
( SD).
vivo competition assay. Mixed lymphoma populations were pre- B: Lymphoma populations as in A (transduced with GFP-coexpressing vec-
pared by combining GFP-tagged ctrl.-MSCV, p53 null-MSCV, tors) were mixed with their corresponding untransduced primary lympho-
mas (see Experimental Procedures for details), adjusted to 4%–15% GFPctrl.-bcl2, or ctrl.-C9DN lymphoma cells with non-GFP express-
expressing cells (exact flow cytometric values shown as “input”), and trans-ing ctrl. or p53 null counterparts, such that the percentage of
planted (1  106 cells by tail vein injection) into recipient mice. Upon tumorGFP-positive cells ranged between 4%–15% (Figure 1B, “in-
formation, lymph nodes were assessed for the fraction of GFP positive cells
put”). These populations were immediately injected into the tail by flow cytometry (“tumor”). Shown is one representative data set out of
vein of syngeneic animals, where they were allowed to expand at least two experiments each.
in vivo. The peripheral lymph nodes (LN) of tumor-bearing mice
were resected when they achieved a well-palpable size (5 mm
diameter) (Schmitt et al., 2000b), after which lymphoma cells tive to unlabeled ctrl. lymphoma cells, such that virtually all of
were isolated and subjected to flow cytometry to determine the the recovered lymphoma cells were GFP-positive (Figure 1B,
percentage of GFP-positive cells (“tumor,” i.e., the percentage top panels). This effect was also p53-dependent, since p53 null
of cells expressing the transduced gene). Importantly, the per- cells expressing the antiapoptotic genes showed little (Bcl2), if
centage of ctrl.-MSCV cells mixed with uninfected ctrl. lympho- any (C9DN), enrichment relative to uninfected p53 null cells
mas did not change during lymphoma expansion (Figure 1B, (Figure 1B, bottom). These results, together with those pre-
upper left), indicating that there was no positive or negative sented in Figure 1A, indicate that Bcl2 and C9DN target apopto-
selection against the MSCV vector [(%GFPtumor)/(%GFPinput)  sis but do not affect nonapoptotic functions of p53. Hence,
s.d.  0.93  0.27)]. Like nullizygosity for p53, expression of like p53 inactivation, disruption of apoptosis provides a potent
selective advantage in vivo.Bcl2 or C9DN in ctrl. cells resulted in dramatic enrichment rela-
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Figure 2. Genetic lesions compromising p53-
mediated apoptosis protect from p53 deletion
in lymphoma development
A: Myc-transgenic p53/ or p53/ offspring
were generated by crossbreeding, and fetal liv-
ers were isolated at gestational age E13.5–E18.5.
Fetal liver cells transduced with MSCV, bcl2, or
C9DN constructs coencoding GFP were systemi-
cally reconstituted in lethally irradiated recipi-
ents. The time between transplantation and
manifestation of palpable peripheral lymph
node (LN) enlargements was scored as “la-
tency.”
B: Tumor latency in recipient animals reconstitu-
ted with myc-transgenic p53/ or p53/ fetal
liver cells transduced with the indicated vectors
(n  43, 38, 14, 14, 13 for p53/HSC-MSCV
[hatched black line], p53/HSC-bcl2 [hatched
blue line], p53/HSC-MSCV [red], p53/HSC-bcl2
[blue], and p53/HSC-C9DN [green], respec-
tively).
C: Tumor latency in p53/HSC-C9DN derived tu-
mors, stratified by their GFP status (GFP-negative,
n  8, hatched red line; GFP-positive, n  5,
green line). GFP status was assessed by flow cy-
tometry at the time of tumor manifestation.
D: GFP expression status in stem cell transfer-
derived lymphomas to indicate dependency of
the formed tumor on the introduced transgene
(top), and corresponding genomic status of the
p53 genes (p53/ is included as positive control;
bottom). Shown are two representative exam-
ples of each genotype.
E-myc lymphomas arising in p53/ mice invariably lose MSCV-bcl2 transduced HSC derived from E-myc (p53/)
transgenic mice developed lymphomas more rapidly than ani-the wild-type p53 allele (Hsu et al., 1995; Schmitt et al., 1999).
To determine whether disruption of apoptosis downstream of mals reconstituted with their MSCV-transduced counterparts
(P 	 0.0001; 25% tumor incidence at day 24 for MSCV-bcl2p53 alleviates pressure to inactivate p53 during lymphoma de-
velopment, we examined the impact of Bcl2 or C9DN expression versus day 128 for MSCV; Figure 2B).
As expected, mice reconstituted with MSCV-transducedon onset latency and p53 status of E-myc lymphomas arising
from p53/ cells. We introduced MSCV, MSCV-bcl2, or MSCV- p53/ HSC developed lymphomas (p53/HSC-MSCV) extremely
rapidly compared to mice receiving MSCV-transduced p53/C9DN into preneoplastic, E-myc transgenic hematopoietic
stem cells (HSC) from fetal livers of p53/ mice, and propagated HSC (P 	 0.0001; Figure 2B). The percentage of GFP-positive
tumors in this cohort was in the range of the infection efficiencythe transduced populations in nontransgenic, lethally irradiated
recipient animals (Figure 2A). Since all animals were reconstitu- of the fetal liver cells used to reconstitute the lethally irradiated
recipients (5%–30%), again suggesting that there was no posi-ted with stem cells that activate myc during B cell development,
we anticipated that most animals would develop lymphomas. tive or negative selection for the MSCV vector. Mice reconstitu-
ted with bcl2-transduced p53/ cells developed lymphomasThis approach provides a rapid alternative to generating and
crossing transgenic mice for producing complex tumor geno- (p53/HSC-bcl2) even more rapidly (P	 0.0001 versus p53/HSC-
MSCV; P  0.03 versus p53/HSC-MSCV; Figure 2B). In thistypes. Indeed, as has been observed in studies using germline
transgenics (Strasser et al., 1990), animals reconstituted with context, 100% of the lymphomas were GFP-positive (14/14
CANCER CELL : APRIL 2002 291
A R T I C L E
Table 1. Designation (in bold) of lymphomas with defined genetic lesions
Infection of established lymphomas Infection of hematopoietic stem cells
Normal cell Retroviral (lymphoma develops in the (lymphoma develops in the presence
genotypea,b construct absence of the transduced gene) of the transduced gene)
myc p53/ no ctrl. ctrl.HSC
MSCV ctrl.-MSCV ctrl.HSC-MSCV
MSCV-bcl2 ctrl.-bcl2 ctrl.HSC-bcl2
MSCV-C9DN ctrl.-C9DN ctrl.HSC-C9DN
myc p53/ no p53-null p53-nullHSC
MSCV p53-null-MSCV p53-nullHSC-MSCV
MSCV-bcl2 p53-null-bcl2 p53/HSC-bcl2
MSCV-C9DN p53-null-C9DN p53/HSC-C9DN
a Lymphomas arising from / cells (no targeted gene deletion) form as “controls” (ctrl.).
b Lymphomas arising from / cells not preserving a functional wild-type sequence are considered “null.”
cases), indicating a strong selection for the presence of Bcl2. leading to destruction of the normal lung architecture (Figure
3B). Hence, disruption of apoptosis, but not primarily p53 loss,Lymphoma onset in mice reconstituted with C9DN-transduced
p53/ HSC was similar to the p53/HSC-MSCV group (P 	 enables tumor cells to override natural growth barriers and to
invade more aggressively into visceral organs outside the0.0001 versus p53/HSC-MSCV), but only a subset was GFP-
positive (5/13 cases). Of note, there was no difference in the lymphoid compartments.
This aggressive growth pattern was further documentedtumor onset between GFP-positive versus -negative lympho-
mas within the p53/HSC-C9DN group (Figure 2C). using whole-body fluorescence imaging, which allows visualiza-
tion of GFP-tagged cells in live mice (Yang et al., 2000). Consis-The expression of Bcl2 or C9DN in E-myc lymphomas
correlated precisely with the p53 status of the lymphomas. Irre- tent with the histopathological findings, ctrl.-MSCV lymphomas
were typically restricted to the LN, bone marrow, and spleenspective of their GFP status, most of the lymphomas arising from
p53/-MSCV HSC lost the wild-type p53 allele and became p53 (Figure 4). In stark contrast, p53 nullHSC-MSCV and p53/HSC-
bcl2 lymphomas were more disseminated, apparently invadingnull (13/14 cases; hereafter designated as p53 nullHSC-MSCV;
Figure 2D, lanes 1 and 2; see also Table 1). In contrast, virtually liver, kidneys, lung, and brain, despite comparable LN enlarge-
ments (Figure 4). Therefore, disruption of apoptosis downstreamall of the p53/HSC-bcl2 lymphomas retained the wild-type p53
allele (12/13 cases; Figure 2D, lanes 3 and 4). Remarkably, the of p53 produces tumors that recapitulate the aggressive behav-
ior of p53 mutant tumors.subset of p53/HSC-C9DN lymphomas that was GFP-positive
(and, hence, expressed C9DN; Figure 2D, lane 5) retained the p53 loss is also associated with severe disturbances in sev-
eral cell-cycle checkpoints and genomic integrity, leading to thewild-type p53 allele (5/5), whereas those tumors that were GFP-
negative did not (8/8; Figure 2D, lane 6). Importantly, the reten- hypothesis that an essential role for p53 in tumor suppression
is to limit the occurrence of secondary mutations that fuel tumortion of wild-type p53 in tumors expressing Bcl2 or C9DN cannot
be attributed to a cell division bias (i.e., less cell doublings progression. To evaluate the contribution of checkpoint defects
to myc-induced lymphomagenesis, we examined the DNA dam-required to achieve a similar tumor burden), since the wild-type
p53 allele was retained even after passaging p53/HSC-bcl2 and age-induced G1 and G2 checkpoints in primary cultures of E-
myc lymphomas. As predicted, p53 nullHSC-MSCV lymphomap53/HSC-C9DN lymphomas through syngeneic recipient mice
(data not shown). Therefore, disruption of apoptosis alleviates cells displayed profound defects in the radiation-induced G1
checkpoint, showing only a modest reduction in the S phasethe pressure to inactivate p53.
In addition to accelerating lymphomagenesis, p53 loss re- fraction and a G2 accumulation 20 hr after -irradiation (Figure
5A). Similarly, -irradiated p53 nullHSC-MSCV lymphoma cellssults in E-myc lymphomas that are extremely aggressive
(Schmitt et al., 1999). To determine how disruption of apoptosis were unable to arrest properly in G2, as documented using a
“mitotic trap” assay that measures the inappropriate passagedownstream of p53 impacts tumor behavior, we examined the
pathology of p53/ lymphomas in which the wild-type p53 allele of cells through G2 into mitosis in the presence of the spindle
poison nocodazole (Bunz et al., 1998) (Figure 5B). Many of thesewas retained owing to expression of Bcl2 or C9DN. The “starry
sky” morphology of cell clusters undergoing apoptosis is a hall- inappropriately proliferating cells have a 4N DNA content,
indicative of endoreduplication. (Figure 5C). Of note, some p53mark of E-myc lymphomas and related human malignancies
(Adams et al., 1985; Hecht and Aster, 2000); accordingly, most nullHSC-MSCV lymphoma cells even underwent endoreduplica-
tion in the presence of nocodazole alone, suggesting a spindlectrl.-MSCV lymphomas contained heterogeneous clusters of
dying cells that were TUNEL-positive (Figure 3A). However, checkpoint defect (Cross et al., 1995) or a subsequent G1 arrest
following adaptation to nocodazole (Lanni and Jacks, 1998).much like p53 nullHSC-MSCV lymphomas, p53/HSC-bcl2 or
p53/HSC-C9DN lymphomas were relatively homogeneous and Although p53/HSC-bcl2 lymphomas were identical to p53 mu-
tant tumors with respect to accelerated tumor onset and inva-contained few apoptotic cells (Figure 3A). We previously re-
ported that p53 null lymphomas readily invade visceral organs, siveness, they did not display the checkpoint defects associated
with p53 loss. Indeed, consistent with their retention of p53,whereas most control lymphomas remain restricted to the
lymphoid compartment (Schmitt et al., 1999) (Figure 3B). Simi- p53/HSC-bcl2 lymphomas preserved an intact G1 and G2
checkpoint, and did not undergo endoreduplication in the pres-larly, p53/HSC-bcl2 and p53/HSC-C9DN lymphomas grow in a
highly invasive manner, for example, with pulmonary infiltration ence of spindle poisons. As expected, the p53 retained in these
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Figure 3. Apoptotic defects predispose to ag-
gressive tumors despite retained p53 genes
A: Hematoxilin and eosin (H/E; high power field,
top) stained sections of LN of similar size. Confir-
mation of apoptotic cell death by the FITC-
based TUNEL reaction in situ (low power field,
bottom).
B: Lung tissue sections obtained from animals
bearing lymphomas as in A showing very little
pulmonary infiltration for p53/-MSCV lym-
phoma cells (far left), but massive lung invasion
by lymphomas reflecting p53-nullHSC-MSCV (left),
p53/HSC-bcl2 (right) and p53/HSC-C9DN (far
right) genetic constellations (H/E, low power
field). Shown are representative examples.
tumors remained functional, since treatment with DNA damag- mutations in human tumors reflects the profound advantage a
developing tumor cell receives by simultaneous loss of all p53ing agents induced p53 and its transcriptional target p21 (Fig-
ure 5D). functions (Vogelstein et al., 2000). However, in this study, we
observe that this is not always the case. In fact, by introducingThe most common form of genomic instability that is associ-
ated with p53 loss is aneuploidy, although not all p53 mutant genes into hematopoietic stem cells of different genetic back-
grounds prior to spontaneous tumor formation and by studyingtumors display this phenotype (Bunz et al., 2002; Lu et al., 2001).
Indeed, freshly isolated p53 nullHSC-MSCV lymphomas were usu- the resulting tumor behavior in recipient mice, we demonstrate
that disruption of apoptosis downstream of p53 phenocopiesally aneuploid, as measured by DNA content profiles (Schmitt
et al., 1999) (Figure 6, top; 4/7) and by direct counting of chromo- p53 loss with respect to its impact on tumor onset and dissemi-
nated growth pattern. In contrast, other p53-related defects,somes in metaphase spreads (mean 48.2; range 39–107 chro-
mosomes; n  5). In contrast, p53/HSC-bcl2 and GFP-positive while present, have little if any effect.
The importance of apoptosis for p53-mediated tumor sup-p53/HSC-C9DN lymphoma cells did not display aneuploidy but
remained pseudodiploid with a normal chromosome count of pression has been suggested from correlative studies linking
p53 loss to apoptotic defects during the progression of murine40 (mean 40.0 and 40.8; range 39–43 and 40–43; n  7 and
n  3; [compared to p53 nullHSC-MSCV] P 	 0.0001 and P  and human tumors (Attardi and Jacks, 1999; Bardeesy et al.,
1995), as well as by functional studies demonstrating that strictly0.0017, respectively, Figure 6). Importantly, p53/HSC-C9DN
lymphomas that were GFP-negative and became p53 deficient antiapoptotic activities can accelerate tumorigenesis in trans-
genic mice (Eischen et al., 2001; Strasser et al., 1990; Yin etbehaved like p53 nullHSC-MSCV cells (mean 45.8; range 39–75).
Thus, apoptotic defects in the presence of intact p53 do not al., 1997). Furthermore, certain p53 wild-type tumors harbor
mutations that can suppress apoptosis downstream of p53 (Io-necessarily impose chromosomal instability. As a result, the
integrity of p53-dependent cell-cycle checkpoints and chromo- nov et al., 2000; Meijerink et al., 1998; Soengas et al., 2001),
and some tumor-derived p53 mutants are defective at inducingsomal stability were uncoupled from aggressive tumor behavior
and, as such, appeared to be byproducts of p53 loss. apoptosis but not cell-cycle arrest (Aurelio et al., 2000). Never-
theless, because of the many other defects present in p53 mu-
tant tumor cells, it has been difficult to assess the overall contri-Discussion
bution of apoptosis to p53-mediated tumor suppression. Here
we demonstrate that inactivation of apoptosis downstream ofGiven the involvement of p53 in many antiproliferative pro-
cesses, it is widely assumed that the high frequency of p53 p53 alleviates pressure to mutate p53 during myc-induced lym-
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It is noteworthy that a dominant-negative caspase 9 allele
can accelerate tumor development in the E-myc transgenic
mouse, albeit not as consistently as Bcl2. This widely used
mutant allele is known to interfere with the function of the apo-
ptosome (Fearnhead et al., 1998), which is a multiprotein com-
plex including Apaf-1 and Caspase-9 that acts with cytochrome
c released from mitochondria to promote apoptosis (Schuler
and Green, 2001). Consistent with these results, apaf-1 and
caspase 9 null fibroblasts are resistant to p53-induced apopto-
sis and prone to oncogenic transformation (Soengas et al.,
1999). Nevertheless, it is clear that loss of caspase 9 function
does not always produce a long-term survival advantage (Water-
house et al., 2001). Moreover, while we show that C9DN can
act downstream of p53 to block apoptosis, we cannot rule
out the possibility that it has additional targets besides the
apoptosome.
As has been observed in many settings (Eischen et al., 1999;
Elson et al., 1995; Gaidano et al., 1991; Gao et al., 2000; Hsu
et al., 1995; McCormack et al., 1998; Schmitt et al., 1999), p53
inactivation during myc-induced lymphomagenesis is associ-
ated with checkpoint defects as well as gross aneuploidy. Al-
though it is clear that genomic instability can contribute to tu-
morigenesis (Honchel et al., 1995), lymphomas arising in the
presence of Bcl2 or C9DN and retaining wild-type p53 were as
aggressive as those harboring p53 mutations, but preserved key
cell-cycle checkpoints and remained pseudodiploid. Therefore,
the cell-cycle checkpoint defects and aneuploidy associated
with p53 mutations are byproducts of p53 loss and do not
contribute to lymphomagenesis, even though they are present.
This conclusion has profound implications, for it suggests that
the aggressive behavior of some p53 mutant tumors can be
attributed to the immediate effects of p53 loss rather than the
secondary consequences of the increased genomic instability.
More importantly, our results imply that not all abnormalities
observed in p53 mutant tumors are relevant to the neoplastic
phenotype.
Still, genomic instability and other byproducts of p53 loss—
while not selected for initially—may confer additional capabili-
ties to the tumor as it encounters new stresses or environments,
for example, as might occur following cancer therapy or during
metastatic spread. Indeed, while Bcl2 overexpression produces
lymphomas that are phenotypically identical to p53 mutant tu-
mors, animals harboring E-myc lymphomas overexpressing
Bcl2 have a better prognosis following cancer therapy thanFigure 4. Whole body fluorescence imaging allows visualization of lym-
phoma dissemination those harboring tumors with mutant p53 (Schmitt et al., 2002).
Lymphomas with the indicated genotypes and transduced with a GFP- This implies that other byproducts of p53 loss supply additional
coexpressing retrovirus were transplanted into recipients to monitor lym- capabilities to the tumor that are revealed only under therapy.
phoma dissemination in whole viable animals by GFP fluorescence. At com- These capabilities are not conferred to E-myc lymphomas
parable LN enlargements (e.g., axillar LN, see arrows), p53 null and Bcl2
overexpressing Bcl2. Similarly, the genomic instability that ac-overexpressing lymphomas are much more disseminated, infiltrating liver,
companies p53 inactivation confers no advantage to a trans-kidneys, lung (marked), and brain, while the ctrl.-MSCV lymphoma is re-
stricted to the lymphoid compartment. GFP images are representative ex- formed hamster embryo fibroblast cell line beyond that pro-
amples from several independent time-course experiments per genotype. duced by disruption of apoptosis alone in a xenograft setting,
but is associated with more efficient induction of experimental
metastases (Gurova et al., 2002).
Our results suggest that disruption of apoptosis is sufficient
to explain the occurrence of p53 mutations in human non-Hodg-phomagenesis, implying that apoptosis is the only p53 effector
kin’s lymphoma, and perhaps in other cancers as well. Still,function that limits tumor development in this setting. This ob-
given the complexity of p53 action, it is likely that the contribu-servation is particularly interesting in light of the highly dissemi-
tion of individual effector functions to tumor suppression maynated nature of p53 mutant lymphomas, for it argues that inap-
vary with respect to the tissue type or inducing stimulus. Forpropriate survival in a foreign environment—and not invasion
per se—can contribute to metastatic growth. example, whereas c-Myc activates p53 to promote apoptosis,
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Figure 6. Aggressive lymphomas can maintain regular chromosome counts
Chromosomal instability analyzed by DNA content profiles and chromo-
some counts in metaphase spreads (line at 40 chromosomes indicates the
regular number in mice) of (unselected) p53 nullHSC-MSCV lymphomas and
p53/HSC-bcl2 lymphomas (and p53/HSC-C9DN lymphomas, data not
shown). Histograms reflect mean SD of at least five lymphoma populations
each.
oncogenic Ras can activate p53 to induce a senescence-like
arrest (Serrano et al., 1997). Hence, during ras-initiated tumori-
genesis, disruption of senescence may provide the immediate
advantage to cells acquiring p53 mutations, whereas apoptotic
defects may be byproducts of p53 loss. Defining the crucial
p53 effector functions that act naturally to suppress the develop-
ment of different tumor types will be important for designing
targeted therapeutics that are likely to be most effective against
p53 mutant tumors.
Experimental procedures
Generation of lymphomas with defined genetic lesions
E-myc transgenic mice were crossbred to p53/ mice (both C57BL/6
inbred strains) in order to obtain myc-transgenic p53/ offspring. Genotyp-
ing was performed by PCR as described (Schmitt et al., 1999). Mice were
sacrificed by CO2 euthanasia when peripheral lymph node enlargements
became well-palpable, about 5 mm in the longest diameter. Lymphomas
were either fixed for histopathological evaluation, or processed to single cell
suspensions for subsequent assays and cell culture as described (Schmitt
et al., 1999). Of note, newly cultured control lymphomas displaying reduced
trapped in mitosis at 20 hr after -irradiation (compare to untreated G2/M
Figure 5. Aggressive growth characteristics do not require checkpoint de- fraction in A).
fects C: As in B, but cells were subjected to DNA content analysis to assess DNA
content4N indicating endoreduplication. Data reflect experiments basedA: Cell-cycle profile analysis of freshly isolated p53 nullHSC-MSCV and
on two or more preparations per genotype. Results obtained in the GFP-p53/HSC-bcl2 lymphomas untreated and 20 hr after exposure to 8 Gy
positive p53/HSC-C9DN group were similar to A–C in the p53/HSC-bcl2 group-irradiation (note that for clarity, only pseudodiploid p53 nullHSC-MSCV lym-
(data not shown).phomas were used in checkpoint analyses).
D: Freshly isolated p53/HSC-bcl2 lymphomas untreated and 1 and 4 hr afterB: The same lymphomas were irradiated as described, but cultures were
exposure to 4 Gy -irradiation were subjected to p21 immunoblot analysis.supplemented with 0.1 g/ml of the mitotic spindle poison nocodazole 2 hr
Shown also is an 
-tubulin (Tub) blot to document equal protein loading.after -irradiation. The histograms (mean  SD) show the fraction of cells
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spontaneous cell death by trypan blue exclusion similar to p53 null lympho- expressing lymphomas were mixed with their corresponding untransduced
mas were excluded since they might have acquired secondary mutations in counterparts (or MSCV transduced p53 null lymphomas with untransduced
the p53 pathway (Eischen et al., 1999; Schmitt et al., 1999). Day 13.5–18.5 ctrl. lymphomas) in order to adjust the GFP-positive fraction to 15% or
pregnant mice from a myc-transgenic to p53/ cross (or to p53/ for some less. Actual values of GFP-expressing fractions were documented by flow
experiments) were sacrificed to obtain fetal livers, which were minced and cytometry. Cells were transplanted as described (Schmitt et al., 2000a), and
grown at approximately 3 106 cells/ml in conditions supporting hematopoi- the percentage of GFP-positive lymphoma cells was assessed after tumor
etic stem cell growth (37% DMEM, 37% Iscove’s modified Dulbecco’s Me- formation by flow cytometry.
dium [Gibco], supplemented with 20% fetal calf serum, 2% L-glutamine [200
mM], 100 U/ml penicillin/streptomycin, 5  105 M 2-mercaptoethanol, 4% Assessing p53 functionality and cytochrome c release
0.45 m filtered WEHI-3B supernatant, 0.2 ng/ml recombinant murine in- To assess p53 function, lymphomas were treated with a single dose of 4
terleukin-3, 2 ng/ml recombinant murine interleukin-6, and 20 ng/ml recombi- Gy -irradiation and harvested 1 or 4 hr later. Lysates were subject to
nant murine stem cell factor [all cytokines from Research Diagnostics] at immunoblotting using a polyclonal antibody against p21 (C-19, Santa Cruz,
37C in a humidified 5% CO2 atmosphere). 1:500 dilution) and 
-tubulin as a loading control (Schmitt et al., 1999). To
A dominant-negative caspase 9 (C9DN) was generated by site-directed measure cytochrome c release, lymphoma cells expressing Bcl2 or C9DN,
mutagenesis of an adenine to thymine at nucleotide position 973 of the respectively, were left untreated or treated with either 4 Gy -irradiation or
murine cDNA resulting in a cysteine to serine exchange in the catalytic center incubated with 10 g/ml mafosphamide (MAF, a cyclophosphamide analog
QACGG (Pan et al., 1998). This was subcloned into MSCV-IRES-GFP (MSCV- active in vitro; a gift from Asta Medica, Germany) for 6 hr, and subsequently
C9DN). MSCV-bcl2-IRES-GFP (MSCV-bcl2) has been described (Schmitt et subjected to Dounce homogenization and centrifugation to obtain a mem-
al., 2000a). Production of retroviral supernatants and transductions were brane fraction enriched for mitochondria. Protein extracts from equivalent
carried out as previously described (Schmitt et al., 2000a); however, for cell numbers were analyzed by immunoblotting using an anti-cytochrome c
infection of fetal liver cells, virions were collected in stem cell medium (see antibody (556433, Pharmingen, 1:1000 dilution) for the relative amount of
above). High-titer retroviral supernatant was passed through a 0.45 m filter cytochrome c remaining in the mitochondria (Fridman et al., 2001).
and supplemented with 4 g/ml polybrene (Sigma). About 6  106 cells
were infected four times by spinoculation at 600 g for 10 min in 3 ml of Apoptosis, ploidy, and cell-cycle checkpoint assays
retroviral supernatant every 6–8 hr. 24 hr after the last infection, the fraction Cells were treated with a single dose of 4 Gy -irradiation or 3 g/ml MAF
of GFP (green fluorescent protein) expressing cells was measured by flow and fixed in 70% ethanol after a 6 hr incubation. DNA was stained with
cytometry (FACScalibur, Beckton Dickinson), and protein expression of the propidium iodide, and cells were subjected to flow cytometric cell-cycle
bcl2 or C9DN constructs was detected by western blot analysis using anti- profile analysis as described (Schmitt et al., 1999). Apoptosis was assessed
bodies against Bcl2 (13456E, Pharmingen, 1:750 dilution) or Caspase 9 (AAP- as the fraction with sub-G1 DNA content. Cell-cycle parameters were ana-
109, Stressgen, 1:500 dilution). 
-tubulin (B-5-1-2, Sigma, 1:2000 dilution) lyzed using the ModFit LT 2.0 software. Apoptosis of lymphoma cells in situ
served as a loading control (Schmitt et al., 2000a) (data not shown). was visualized using a fluorescence based TUNEL (terminal deoxynucleotidyl
For bone marrow reconstitution experiments, 6- to 8-week old C57BL/6 transferase dUTP nick end labeling) assay (Roche) in accordance with the
recipient mice received a single 10 Gy-dose of total body -irradiation (137Ce- manufacturer’s protocol.
sium source; 0.8 Gy/min), and were reconstituted 6 hr later with approxi-
Numeric karyotypic analysis was performed on DAPI stained metaphase
mately 3 106 viable fetal liver cells by tail vein injection. Mice were housed
spreads. Freshly isolated, p53 nullHSC-MSCV, p53/HSC-bcl2 and p53/HSC-on autoclaved bedding in air-filtered cages and received neomycin-con-
C9DN lymphoma cells were cultured in the presence of 10 g/ml colcemide
taining drinking water. Nonreconstituted, lethally irradiated mice were in-
(Gibco) for 1 hr, incubated in 0.4% prewarmed KCl for 5 min at 37C, and
cluded as controls in every experiment, and typically had to be sacrificed
fixed in a 3:1 methanol/acetic acid solution. The cell suspensions were
between day 12 and 18 post irradiation due to bone marrow aplasia. Animals
spotted onto glass slides to spread out chromosomes in metaphase. Air-
were euthanized upon lymphoma onset, which is defined as the occurrence
dried slides were stained with DAPI (4,6-diamidino-2-phenylindole; 1:1000
of well-palpable peripheral lymph node enlargements. Statistical evaluation
in PBS), and mounted in a DAPI-free medium (Vector). At least 50 meta-
of tumor onset data is based on the log-rank (Mantel-Cox) test for compari-
phases were counted for each lymphoma preparation under a fluorescence
son of the Kaplan-Meier event-time format, and on the unpaired t test for
microscope, and at least three different preparations were analyzed percomparison of means and standard deviations. The genomic p53 status of
genotype. The ability to arrest in G1 upon a DNA damaging insult was testedp53/ derived lymphoma cells was analyzed by allele specific PCR after
in the named genotypes 20 hr after exposure to 8 Gy -irradiation in vitro.short-term culture as described (Schmitt et al., 1999).
Integrity of the G2 checkpoint was tested under the same conditions; how-
ever, 0.1 g/ml of nocodazole (Fluka) was added 2 hr after -irradiation,Whole body imaging of GFP-tagged lymphomas
thereby reproducing the mitotic trap protocol described by Bunz et al. (1998)Living animals underwent total body imaging of GFP-expressing lymphomas
with minor modifications. After 20 hr, aliquots of the cells were either ethanol-(Yang et al., 2000) at several time points after systemic transplantation of
fixed and subjected to DNA content profiling as described above, or fixedlymphoma cells transduced with a GFP-encoding retrovirus. A fluorescence
in a solution containing 3.7% formaldehyde, 0.5% Nonidet P-40, and 10stereo microscope (Leica LZ12), equipped with a 50 W mercury lamp, was
g/ml of the nuclear dye Hoechst 33250 in order to count the fraction ofused for high magnification imaging. Selective excitation of GFP was pro-
cells with mitotic morphology, i.e., nuclei with condensed, homogeneouslyduced through a D425/60 band-pass filter and 470 DCXR dichroic mirror.
stained chromosomes, using a fluorescence microscope. At least 200 cellsEmitted fluorescence was collected through a long-pass filter GG475
were counted per lymphoma preparation, and at least three different prepara-(Chroma Technology) on a 3-chip cooled color CCD camera (C5810, Hama-
tions were analyzed per genotype.matsu Photonics Systems). Images were taken at least in two (typically
perpendicular) levels, and underwent processing for contrast and brightness
Acknowledgmentswith subsequent analysis by the Image Pro Plus 3.1 software (Media Cyber-
netics). Images of 1024  724 pixels were captured directly on a microcom-
We thank A. Harris and T. Jacks for mice; W.S. Pear for the WEHI-3Bputer or continuously through video output on a high resolution VCR (SLV-
murine myelomonocytic leukemia cell line; G. Hannon for a murine caspaseR1000, Sony Corp.). Imaging at lower magnification that visualized the entire
9 construct; K. Sokol for histopathology; L. Bianco, the CSHL animal facilityanimal was carried out in a light box illuminated by blue light fiber optics
and C. Rosenthal for technical assistance; and G. Hannon, S. Lee, M. McCur-(Lightools Research, Inc.) and imaged using the thermoelectrically cooled
rach, and M. Soengas for editorial advice. This work was supported by acolor CCD camera, as described above (Yang et al., 2000).
Special Fellowship from the Leukemia & Lymphoma Society (C.A.S.), the
Laurie Strauss Leukemia Foundation and a NCI postdoctoral training grantLymphoma establishment assays
(J.S.F.), and the Rita Allen Foundation, program project grants CA13106Freshly isolated myc-transgenic p53/ and p53 null lymphoma cells were
and CA87497 from the National Cancer Institute (S.W.L.), and 1 R43 89779transduced with bcl2, C9DN, and an “empty” MSCV-IRES-GFP vector as
control (MSCV) (see Table 1 for nomenclature). Upon transduction, GFP- from the National Cancer Institute (R.M.H.).
296 CANCER CELL : APRIL 2002
A R T I C L E
gene mutations in human tumors and cell lines: updated compilation, revised
formats and new visualisation tools. Nucleic Acids Res. 26, 205–213.
Received: February 2, 2002
Revised: April 1, 2002 Hecht, J.L., and Aster, J.C. (2000). Molecular biology of Burkitt’s lymphoma.
J. Clin. Oncol. 18, 3707–3721.
References
Honchel, R., Halling, K.C., and Thibodeau, S.N. (1995). Genomic instability
in neoplasia. Semin. Cell Biol. 6, 45–52.
Adams, J.M., Harris, A.W., Pinkert, C.A., Corcoran, L.M., Alexander, W.S.,
Hsu, B., Marin, M.C., el-Naggar, A.K., Stephens, L.C., Brisbay, S., andCory, S., Palmiter, R.D., and Brinster, R.L. (1985). The c-myc oncogene
McDonnell, T.J. (1995). Evidence that c-myc mediated apoptosis does notdriven by immunoglobulin enhancers induces lymphoid malignancy in trans-
require wild-type p53 during lymphomagenesis. Oncogene 11, 175–179.genic mice. Nature 318, 533–538.
Huang, D.C., O’Reilly, L.A., Strasser, A., and Cory, S. (1997). The anti-Attardi, L.D., and Jacks, T. (1999). The role of p53 in tumour suppression:
apoptosis function of Bcl-2 can be genetically separated from its inhibitorylessons from mouse models. Cell. Mol. Life Sci. 55, 48–63.
effect on cell cycle entry. EMBO J. 16, 4628–4638.
Aurelio, O.N., Kong, X.T., Gupta, S., and Stanbridge, E.J. (2000). p53 mutants
Ionov, Y., Yamamoto, H., Krajewski, S., Reed, J.C., and Perucho, M. (2000).have selective dominant-negative effects on apoptosis but not growth arrest
Mutational inactivation of the proapoptotic gene BAX confers selective ad-in human cancer cell lines. Mol. Cell. Biol. 20, 770–778.
vantage during tumor clonal evolution. Proc. Natl. Acad. Sci. USA 97, 10872–
Bardeesy, N., Beckwith, J.B., and Pelletier, J. (1995). Clonal expansion and 10877.
attenuated apoptosis in Wilms’ tumors are associated with p53 gene muta-
tions. Cancer Res. 55, 215–219. Kakolyris, S.A., Kaklamanis, L.G., Koukourakis, M.J., Giatromanolaki, A.,
Rousomoustakaki, M., Souglakos, J.C., Reppa, D.K., Georgoulias, V.A., Gat-
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., ter, K.C., and Harris, A.L. (2000). Angiogenesis and p53 expression in the
Sedivy, J.M., Kinzler, K.W., and Vogelstein, B. (1998). Requirement for p53
colorectal adenoma-carcinoma sequence. Oncol. Res. 12, 203–208.
and p21 to sustain G2 arrest after DNA damage. Science 282, 1497–1501.
Kastan, M.B., Zhan, Q., El-Deiry, W.S., Carrier, F., Jacks, T., Walsh, W.V.,
Bunz, F., Fauth, C., Speicher, M.R., Dutriaux, A., Sedivy, J.M., Kinzler, K.W.,
Plunkett, B.S., Vogelstein, B., and Fornace, A.J., Jr. (1992). A mammalianVogelstein, B., and Lengauer, C. (2002). Targeted inactivation of p53 in
cell cycle checkpoint pathway utilizing p53 and GADD45 is defective inhuman cells does not result in aneuploidy. Cancer Res. 62, 1129–1133.
ataxia-telangiectasia. Cell 71, 587–597.
Chiou, S.K., Rao, L., and White, E. (1994). Bcl-2 blocks p53-dependent
Ko, L.J., and Prives, C. (1996). p53: puzzle and paradigm. Genes Dev. 10,apoptosis. Mol. Cell. Biol. 14, 2556–2563.
1054–1072.
Cross, S.M., Sanchez, C.A., Morgan, C.A., Schimke, M.K., Ramel, S., Id-
Lane, D.P. (1992). Cancer. p53, guardian of the genome. Nature 358, 15–16.zerda, R.L., Raskind, W.H., and Reid, B.J. (1995). A p53-dependent mouse
spindle checkpoint. Science 267, 1353–1356. Lanni, J.S., and Jacks, T. (1998). Characterization of the p53-dependent
postmitotic checkpoint following spindle disruption. Mol. Cell. Biol. 18, 1055–Eischen, C.M., Weber, J.D., Roussel, M.F., Sherr, C.J., and Cleveland, J.L.
1064.(1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-
induced lymphomagenesis. Genes Dev. 13, 2658–2669. Lu, X., Magrane, G., Yin, C., Louis, D.N., Gray, J., and Van Dyke, T. (2001).
Selective inactivation of p53 facilitates mouse epithelial tumor progressionEischen, C.M., Roussel, M.F., Korsmeyer, S.J., and Cleveland, J.L. (2001).
without chromosomal instability. Mol. Cell. Biol. 21, 6017–6030.Bax Loss impairs Myc-induced apoptosis and circumvents the selection of
p53 mutations during Myc-mediated lymphomagenesis. Mol. Cell. Biol. 21, McCormack, S.J., Weaver, Z., Deming, S., Natarajan, G., Torri, J., Johnson,
7653–7662. M.D., Liyanage, M., Ried, T., and Dickson, R.B. (1998). Myc/p53 interactions
in transgenic mouse mammary development, tumorigenesis and chromo-Elson, A., Deng, C., Campos-Torres, J., Donehower, L.A., and Leder, P.
somal instability. Oncogene 16, 2755–2766.(1995). The MMTV/c-myc transgene and p53 null alleles collaborate to induce
T- cell lymphomas, but not mammary carcinomas in transgenic mice. Onco-
Meijerink, J.P., Mensink, E.J., Wang, K., Sedlak, T.W., Sloetjes, A.W., de
gene 11, 181–190.
Witte, T., Waksman, G., and Korsmeyer, S.J. (1998). Hematopoietic malig-
nancies demonstrate loss-of-function mutations of BAX. Blood 91, 2991–Evan, G.I., and Vousden, K.H. (2001). Proliferation, cell cycle and apoptosis
2997.in cancer. Nature 411, 342–348.
Pan, G., O’Rourke, K., and Dixit, V.M. (1998). Caspase-9, Bcl-XL, and Apaf-1Fearnhead, H.O., Rodriguez, J., Govek, E.E., Guo, W., Kobayashi, R., Han-
form a ternary complex. J. Biol. Chem. 273, 5841–5845.non, G., and Lazebnik, Y. (1998). Oncogene-dependent apoptosis is medi-
ated by caspase-9. Proc. Natl. Acad. Sci. USA 95, 13664–13669.
Schmitt, C.A., McCurrach, M.E., de Stanchina, E., Wallace-Brodeur, R.R.,
Fridman, J.S., Parsels, J., Rehemtulla, A., and Maybaum, J. (2001). Cyto- and Lowe, S.W. (1999). INK4a/ARF mutations accelerate lymphomagenesis
chrome c depletion upon expression of Bcl-XS. J. Biol. Chem. 276, 4205– and promote chemoresistance by disabling p53. Genes Dev. 13, 2670–2677.
4210.
Schmitt, C.A., Rosenthal, C.T., and Lowe, S.W. (2000a). Genetic analysis of
Gaidano, G., Ballerini, P., Gong, J.Z., Inghirami, G., Neri, A., Newcomb, E.W., chemoresistance in primary murine lymphomas. Nat. Med. 6, 1029–1035.
Magrath, I.T., Knowles, D.M., and Dalla-Favera, R. (1991). p53 mutations
Schmitt, C.A., Wallace-Brodeur, R.R., Rosenthal, C.T., McCurrach, M.E.,in human lymphoid malignancies: association with Burkitt lymphoma and
and Lowe, S.W. (2000b). DNA damage responses and chemosensitivity inchronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 88, 5413–5417.
the E-myc mouse lymphoma model. Cold Spring Harb. Symp. Quant. Biol.
Gao, Y., Ferguson, D.O., Xie, W., Manis, J.P., Sekiguchi, J., Frank, K.M., LXV, 499–510.
Chaudhuri, J., Horner, J., DePinho, R.A., and Alt, F.W. (2000). Interplay of
Schmitt, C.A., Fridman, J.S., Yang, M., Lee, S., Baranov, E., Hoffman, R.M.,p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and
and Lowe, S.W. (2002). A senescence program controlled by p53 and p16INK4adevelopment. Nature 404, 897–900.
contributes to the outcome of cancer therapy. Cell, in press.
Gurova, K.V., Kwek, S.S., Koman, I.E., Komarov, A.P., Kandel, E., Nikiforov,
Schuler, M., and Green, D.R. (2001). Mechanisms of p53-dependent apopto-M.A., and Gudkov, A.V. (2002). Apoptosis inhibitor as a suppressor of tumor
sis. Biochem. Soc. Trans. 29, 684–688.progression: expression of bcl-2 eliminates selective advantages for p53-
deficient cells in the tumor. Cancer Biol. Ther. 1, 39–44.
Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. (1997).
Oncogenic ras provokes premature cell senescence associated with accu-Hainaut, P., Hernandez, T., Robinson, A., Rodriguez-Tome, P., Flores, T.,
Hollstein, M., Harris, C.C., and Montesano, R. (1998). IARC Database of p53 mulation of p53 and p16INK4a. Cell 88, 593–602.
CANCER CELL : APRIL 2002 297
A R T I C L E
Smith, M.L., and Fornace, A.J., Jr. (1995). Genomic instability and the role Vogelstein, B., Lane, D., and Levine, A.J. (2000). Surfing the p53 network.
Nature 408, 307–310.of p53 mutations in cancer cells. Curr. Opin. Oncol. 7, 69–75.
Waterhouse, N.J., Goldstein, J.C., von Ahsen, O., Schuler, M., Newmeyer,Soengas, M.S., Alarcon, R.M., Yoshida, H., Giaccia, A.J., Hakem, R., Mak,
D.D., and Green, D.R. (2001). Cytochrome c maintains mitochondrial trans-T.W., and Lowe, S.W. (1999). Apaf-1 and caspase-9 in p53-dependent apo-
membrane potential and ATP generation after outer mitochondrial membraneptosis and tumor inhibition. Science 284, 156–159.
permeabilization during the apoptotic process. J. Cell Biol. 153, 319–328.
Soengas, M.S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, Yang, M., Baranov, E., Jiang, P., Sun, F.X., Li, X.M., Li, L., Hasegawa, S.,
X., McCombie, R., Herman, J.G., Gerald, W.L., Lazebnik, Y.A., et al. (2001). Bouvet, M., Al-Tuwaijri, M., Chishima, T., et al. (2000). Whole-body optical
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature imaging of green fluorescent protein-expressing tumors and metastases.
409, 207–211. Proc. Natl. Acad. Sci. USA 97, 1206–1211.
Strasser, A., Harris, A.W., Bath, M.L., and Cory, S. (1990). Novel primitive Yin, C., Knudson, C.M., Korsmeyer, S.J., and Van Dyke, T. (1997). Bax
lymphoid tumours induced in transgenic mice by cooperation between myc suppresses tumorigenesis and stimulates apoptosis in vivo. Nature 385,
637–640.and bcl-2. Nature 348, 331–333.
298 CANCER CELL : APRIL 2002
